Clinical Pipeline

Clinical Pipeline

Clinical trials for the treatment of HPV-associated cancers

ADXS-HPV, Advaxis’ lead drug candidate, is in clinical trials for HPV-associated cancers. In addition, the company has a preclinical program with 15 distinct immunotherapies in development for cancers and infectious diseases.

Advaxis Clinical Pipeline

Candidate Indication Pre Phase 1 Phase 2 Phase 3

ADXS-HPV

Cervical Cancer, India

Pre-Clinical Phase completed
Phase 1 completed
Phase 2 completed
Phase 3 in progress

Cervical Cancer

Pre-Clinical Phase completed
Phase 1 completed
Phase 2 in progress
Phase 3 not started

Head & Neck Cancer*1

Pre-Clinical Phase completed
Phase 1 in progress
Phase 2 not started
Phase 3 not started

Anal Cancer2

Pre-Clinical Phase completed
Phase 1 in progress
Phase 2 not started
Phase 3 not started

ADXS-PSA

Prostate Cancer

Pre-Clinical Phase completed
Phase 1 in progress
Phase 2 not started
Phase 3 not started

ADXS-cHER2

Breast Cancer

Pre-Clinical Phase in progress

Veterinary Program

ADXS-cHER2

Canine Osteosarcoma

Pre-Clinical Phase completed
Phase 1 completed
Phase 2 in progress
Phase 3 not started

* Orphan Drug Designation Granted

  1. Icahn School of Medicine at Mount Sinai & Cancer Research UK
  2. BrUOG: Brown University Oncology Group